ABT · News · 20260829N
CGM Market Demand
ABBOTT LABORATORIES · 2026-08-29 · Importance 34 · Surprise 42 · In source text
Abbott and Dexcom are anticipating expanded Medicare coverage for continuous glucose monitors (CGMs) to include people with Type 2 diabetes who do not use insulin. The expansion could broaden access to glucose sensors for millions of Americans and materially enlarge the addressable CGM market. Dexcom estimates approximately 25 million non-insulin-using Type 2 diabetics, while Abbott expects an additional 10 million Medicare recipients to become eligible.
Key facts
- Abbott expects 10 million more Medicare recipients to become eligible for CGMs under the anticipated Medicare coverage expansion. source
- Dexcom and Abbott are anticipating a significant expansion in Medicare coverage for continuous glucose monitors (CGMs) to include people with Type 2 diabetes who do not take insulin. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott expects 10 million more Medicare recipients to become eligible for CGMs under the anticipated Medicare coverage expansion. |